# A Trial to Evaluate Two Schedules of MS275 in Combination With 5AC in Elderly Patients With Acute Myeloid Leukemia (AML)

> **NCT01305499** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Hetty Carraway** · enrollment: 52 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Entinostat days 3, 10
- **DRUG:** 5AC
- **DRUG:** Entinostat days 10,17

## Key facts

- **NCT ID:** NCT01305499
- **Lead sponsor:** Hetty Carraway
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2011-07-01
- **Primary completion:** 2021-09-30
- **Final completion:** 2024-09-30
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2024-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01305499

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01305499, "A Trial to Evaluate Two Schedules of MS275 in Combination With 5AC in Elderly Patients With Acute Myeloid Leukemia (AML)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01305499. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*